hotspot -WSS

hotspot

author：focus 2025-09-30 00:46:15 - browse：2787

Adam's take main illustration — Molly Ferguson/STAT

Thoughts about Cytokinetics after Wednesday night’s financing announcement:

1. Management is raising $500 million at $51 per share, when the stock was at $45 per share before the aficamtem study readout in December. That’s shocking. Somehow, management has not only removed all the M&A premium from the stock, but much or most of aficamtem’s value, too.

2. Omecamtiv’s resurrection: Are you kidding me? No one thinks bringing back this heart failure drug is a good idea, except management. Making it worse, the terms of the Royalty Pharma loan are, again, shocking. All the risk is borne by Cytokinetics. Royalty, in fact, may do better if omecamtiv fails.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： FDA seeks to regulate lab

entertainment

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Medicare threatens to cut off funding for HCA's Mission hospital

Inequities make cancer less preventable for women: report

Listen: Who gets the credit for GLP

PhRMA lawsuit over Medicare drug price negotiation tossed

Mindstrong's demise and the future of mental health care

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Affirmative action in medical school literally saved lives

Readout LOUD podcast: How biotech is using artificial intelligence

Psychedelics group wrestles with new pharma identity

Medicare threatens to cut off funding for HCA's Mission hospital

Affirmative action in medical school literally saved lives

How the Dana

Medical records are filled with copy

To avoid data mishandling cases, universities eye AI and other tools

Anesthesiologist group: stop taking Ozempic before surgery

How one patient went off dialysis — and others can too

Wikipedia

BioAge raises $170M for combination therapy with Zepbound

PhRMA lawsuit over Medicare drug price negotiation tossed

Paxlovid should be available without a positive Covid test

FDA advisers vote against ALS treatment from BrainStorm

Gilead might be held responsible for not developing a drug

Vaccine advisory panel ACIP left half staffed by HHS

entertainment

leisure time

hotspot

focus